Abivax S.A.
ABVX · XNASCIK 1956827fmd_1861G693QK4YE175W5RX24CNJJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Dec 31, 2025, 11 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Research and development | 48 | 48 | 103 | 147 | 178 |
| Operating income | (41) | (65) | (127) | (173) | (246) |
| Interest expense | 4 | 7 | 28 | 17 | 112 |
| Income before taxes | (42) | (61) | (148) | (176) | (330) |
| Income tax expense | 0 | 0 | 0 | 0 | 6 |
| Net income from continuing operations | (42) | (61) | (148) | (176) | (336) |
| Net income | (42) | (61) | (148) | (176) | (336) |